BioCryst (BCRX) Q1 2026 earnings review
Astria Charge Obscures Solid Non-GAAP Core Performance
BioCryst reported a massive GAAP operating loss of $701.6 million in Q1 2026, driven entirely by a $697.8 million non-cash charge from the Astria Therapeutics acquisition. Beneath this accounting noise, the core business remains stable. ORLADEYO revenue reached $148.3 million (+11% YoY), overcoming typical Q1 insurance reauthorization headwinds. Non-GAAP operating profit was a healthy $54.2 million. Management is aggressively monetizing its new pipeline, already out-licensing European rights to navenibart for $70 million upfront, bolstering pro-forma cash to $330.8 million and funding operations without market dilution.
🐂 Bull Case
BioCryst immediately de-risked the newly acquired navenibart asset by out-licensing European rights to Neopharmed Gentili for $70M upfront and up to $275M in milestones. This injects non-dilutive capital directly into the US pivotal trials.
Excluding the massive Astria one-time charges, the company delivered $54.2M in non-GAAP operating profit, proving the ORLADEYO commercial engine can sustain the R&D pipeline.
🐻 Bear Case
ORLADEYO YoY revenue growth has decelerated sequentially for four straight quarters, dropping from 51% in 25Q1 to just 11% in 26Q1, signaling the drug is maturing and peak market penetration is approaching.
A -$721.8M GAAP net loss makes traditional screening metrics unusable for investors, requiring reliance on heavily adjusted non-GAAP figures that exclude $16M in stock-based comp and $42M in severance/payouts.
⚖️ Verdict: ⚪
Hold. The strategic pivot toward rare diseases and the rapid European partnership for navenibart are excellent capital allocation moves. However, decelerating ORLADEYO growth and massive accounting distortions cap immediate upside.
Key Themes
Navenibart European Partnership Accelerates Liquidity
The ink on the Astria acquisition barely dried before BioCryst partnered the European rights for navenibart. Securing $70 million upfront with up to $275 million in milestones and 18-30% tiered royalties is a textbook example of efficient capital deployment. This boosts pro-forma cash to $330.8 million, ensuring the Phase 3 ALPHA-ORBIT trial is fully funded without tapping equity markets.
ORLADEYO Growth Deceleration Contradicts the 'Comparable' Narrative
Management highlights that ORLADEYO grew '+21% YoY on a comparable basis excluding European revenue.' However, this masks a broader deceleration. Total ORLADEYO revenue actually shrank sequentially from $151.0M in 25Q4 to $148.3M in 26Q1. While Q1 reauthorization friction is a known seasonal headwind, the trajectory confirms ORLADEYO is entering a stable, slower-growth phase.
Massive GAAP Distortions from Astria Deal
The $697.8 million non-cash in-process R&D charge for navenibart decimated GAAP metrics, pushing operating loss to $701.6 million. Additionally, BioCryst backed out $12.3 million in severance/retention and $29.1 million in post-combination option payouts. Investors must strictly monitor non-GAAP OpEx to track the true cash burn rate.
BCX17725 Advancing to Longer Dosing
The KLK5 inhibitor for Netherton syndrome (BCX17725) has progressed to Part 4 of its Phase 1 trial. Initiating three-month dosing in up to 12 patients is a critical de-risking step. With data expected by late 2026, this asset remains the primary organic pipeline driver outside of the acquired navenibart program.
Avoralstat Discontinuation
BioCryst officially ended the development of avoralstat for diabetic macular edema (DME). While framed as 'focusing the pipeline on rare diseases,' abandoning an asset rather than spinning it out or partnering it (as teased in prior quarters) suggests the underlying clinical or economic data did not support further investment.
Strong Underlying Gross Margins
Despite the GAAP noise, cost of product sales remained minimal at $5.4 million against $156.4 million in total revenue, yielding a stellar ~96.5% gross margin. This high-margin cash engine is what allows the company to aggressively fund its clinical pipeline.
Other KPIs
Reversing sharply from a near-breakeven $0.03M profit in 25Q1, entirely due to the $697.8M in-process R&D charge associated with the Astria acquisition and subsequent integration costs.
Accelerating from $43.5 million in 25Q1. This metric excludes $755.8M in Astria-related charges and stock-based compensation, highlighting that the underlying commercial business remains highly profitable and capable of self-funding.
Stable. The company ended Q1 with $260.8 million in cash and investments, but the subsequent $70M payment from Neopharmed Gentili pushes total functional liquidity above $330M, providing a robust runway for Phase 3 execution.
Guidance
Stable. Management maintained guidance, which implies a mid-single-digit YoY growth rate (approx. 5.6% at the midpoint) compared to the $601 million generated in FY25. This confirms a significant deceleration from the 38% growth seen in FY25.
Stable. Maintained from prior guidance. The ~15M gap between ORLADEYO and Total Revenue accounts for legacy products like RAPIVAB and minor license/other revenues.
Stable. Maintained guidance. Excludes stock-based compensation, restructuring, and transaction costs. Management's ability to maintain this level despite absorbing the Astria pipeline indicates strict cost control measures are in place.
Key Questions
Path to Peak Sales
With ORLADEYO revenue growth decelerating to 11% YoY, how heavily does the trajectory toward the $1 billion peak sales target rely on the new pediatric formulation versus core adult market share gains?
Avoralstat Cancellation
Avoralstat was discontinued to 'focus on rare diseases,' but earlier commentary suggested seeking a partner. Did the initial clinical data simply not support external monetization?
BCX17725 Partnership Potential
Given the swift and successful out-licensing of European rights for navenibart, are you actively exploring similar ex-US regional partnerships for BCX17725 to further offset clinical development costs?